J. Pharm. Sci.
| [0039]
|
McGraw-Hill Dictionary of Chemical Terms
| [0049]
|
Stereochemistry of Organic Compounds
| [0049]
|
J. Med. Chem.
| [0077]
|
Cancer research
| [0077]
|
Critical reviews in oncology/haematology
| [0077]
|
Remington's Pharmaceutical Sciences
| [0082]
|
Leukemia
| [0255]
|
Biochemistry
| [0255]
|
Nat. Genet.
| [0255]
|
Blood
| [0255]
|
Genetics
| [0255]
|
Leukemia
| [0255]
|
Cancer Cell
| [0255]
|
Nat Med
| [0255]
|
CA Cancer J Clin
| [0255]
|
Nature
| [0255]
|
Nature
| [0255]
|
Nature
| [0255]
|
J Neurosci
| [0255]
|
Drugs
| [0255]
|
Leukemia
| [0255]
|
Hum Mol Genet
| [0255]
|
Methods
| [0255]
|
Blood
| [0255]
|
Nat Rev Cancer
| [0255]
|
Moz (MYST3, KAT6a) inhibitis senescence via the INK4A-ARF pathway
| [0255]
|
MOZ regulates B cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development
| [0255]
|
Leuk Res
| [0255]
|
Development
| [0255]
|
Genes Dev
| [0255]
|
Cell Cycle
| [0255]
|
Genes Chromosomes Cancer
| [0255]
|
Mol Cell Biol
| [0255]
|